Terms: = Breast cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Treatment
414 results:
1. Impact of chrono-radiotherapy on the prognosis and treatment-related toxicity in patients with locally advanced nasopharyngeal carcinoma: A multicenter propensity-matched study.
Lin J; Lin X; Zheng R; Lin K; Khan M; Huang X; Tian Y; Wang B; Xu B; Yuan Y; Huang Z
Chronobiol Int; 2024 Apr; 41(4):587-597. PubMed ID: 38606920
[TBL] [Abstract] [Full Text] [Related]
2. The effectiveness of couple-based interventions on the marital outcomes of women with genital and breast cancer and their partners: a systematic review and meta-analysis.
Zahedi H; Alizadeh-Dibazari Z; Mirghafourvand M; Sahebihagh MH; Hosseinzadeh M
BMC Cancer; 2024 Mar; 24(1):391. PubMed ID: 38539118
[TBL] [Abstract] [Full Text] [Related]
3. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
4. Age-related phenotypes in breast cancer: A population-based study.
Svanøe AA; Humlevik ROC; Knutsvik G; Sæle AKM; Askeland C; Ingebriktsen LM; Hugaas U; Kvamme AB; Tegnander AF; Krüger K; Davidsen B; Hoivik EA; Aas T; Stefansson IM; Akslen LA; Wik E
Int J Cancer; 2024 Jun; 154(11):2014-2024. PubMed ID: 38319154
[TBL] [Abstract] [Full Text] [Related]
5. Targeting breast cancer with N-Acetyl-D-Glucosamine: Integrating Machine Learning and Cellular Assays for Promising Results.
Baysal Ö; Genç D; Silme RS; Kırboğa KK; Çoban D; Ghafoor NA; Tekin L; Bulut O
Anticancer Agents Med Chem; 2024; 24(5):334-347. PubMed ID: 38305389
[TBL] [Abstract] [Full Text] [Related]
6. Tumor microenvironment and immune system preservation in early-stage breast cancer: routes for early recurrence after mastectomy and treatment for lobular and ductal forms of disease.
Saad HA; Baz A; Riad M; Eraky ME; El-Taher A; Farid MI; Sharaf K; Said HEM; Ibrahim LA
BMC Immunol; 2024 Jan; 25(1):9. PubMed ID: 38273260
[TBL] [Abstract] [Full Text] [Related]
7. Association of clinicopathologic variables and patient preference with the choice of surgical treatment for early-stage breast cancer: A registry-based study.
Söderberg E; Wärnberg F; Wennstig AK; Nilsson G; Garmo H; Holmberg L; Blomqvist C; Sund M; Wadsten C
Breast; 2024 Feb; 73():103614. PubMed ID: 38056168
[TBL] [Abstract] [Full Text] [Related]
8. Immune system and tumor microenvironment in early-stage breast cancer: different mechanisms for early recurrence after mastectomy and chemotherapy on ductal and lobular types.
Andrianto A; Sudiana IK; Suprabawati DGA; Notobroto HB
F1000Res; 2023; 12():841. PubMed ID: 38046195
[No Abstract] [Full Text] [Related]
9. Trends in the pre-operative diagnosis and surgical management of axillary lymph node metastases in women with screen-detected breast cancer.
Duijm LEM; Strobbe LJA; van Breest Smallenburg V; Op de Coul-Froger CL; Setz-Pels W; Vreuls W; van Beek HC; van Bommel RMG; Voogd AC
Breast; 2023 Dec; 72():103593. PubMed ID: 37890215
[TBL] [Abstract] [Full Text] [Related]
10. Using MammaPrint on core needle biopsy to guide the need for axillary staging during breast surgery.
Drapalik LM; Miller ME; Rock L; Li P; Simpson A; Shenk R; Amin AL
Surgery; 2024 Mar; 175(3):579-586. PubMed ID: 37852835
[TBL] [Abstract] [Full Text] [Related]
11. The role of immune checkpoint inhibition in triple negative breast cancer.
Tarekegn K; Keskinkilic M; Kristoff TJ; Evans ST; Kalinsky K
Expert Rev Anticancer Ther; 2023; 23(10):1095-1106. PubMed ID: 37771270
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathologic Profile and Psychosocial Experiences of Nigerian breast cancer Survivors.
Wuraola FO; Olasehinde O; Di Bernardo M; Aderounmu AA; Adisa AO; Omoyiola OZ; Omisore AD; Kingham TP; Mango V; Alatise OI
JCO Glob Oncol; 2023 Sep; 9():e2300022. PubMed ID: 37769219
[TBL] [Abstract] [Full Text] [Related]
13. Prediction of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer by using a deep learning model with 18F-FDG PET/CT.
Bulut G; Atilgan HI; Çınarer G; Kılıç K; Yıkar D; Parlar T
PLoS One; 2023; 18(9):e0290543. PubMed ID: 37708209
[TBL] [Abstract] [Full Text] [Related]
14. BCKDK regulates breast cancer cell adhesion and tumor metastasis by inhibiting TRIM21 ubiquitinate talin1.
Xu C; Yang K; Xuan Z; Li J; Liu Y; Zhao Y; Zheng Z; Bai Y; Shi Z; Shao C; Zhang L; Sun H
Cell Death Dis; 2023 Jul; 14(7):445. PubMed ID: 37460470
[TBL] [Abstract] [Full Text] [Related]
15. MCL1 Inhibition Overcomes the Aggressiveness Features of Triple-Negative breast cancer MDA-MB-231 Cells.
Pratelli G; Carlisi D; Di Liberto D; Notaro A; Giuliano M; D'Anneo A; Lauricella M; Emanuele S; Calvaruso G; De Blasio A
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446326
[TBL] [Abstract] [Full Text] [Related]
16. Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative breast cancer.
Zhang Y; Lv L; Zheng R; Xie R; Yu Y; Liao H; Chen J; Zhang B
Breast Cancer Res; 2023 Jun; 25(1):75. PubMed ID: 37365643
[TBL] [Abstract] [Full Text] [Related]
17. Differentiation between Phyllodes Tumors and Fibroadenomas through breast Ultrasound: Deep-Learning Model Outperforms Ultrasound Physicians.
Shi Z; Ma Y; Ma X; Jin A; Zhou J; Li N; Sheng D; Chang C; Chen J; Li J
Sensors (Basel); 2023 May; 23(11):. PubMed ID: 37299826
[TBL] [Abstract] [Full Text] [Related]
18. Single Nucleotide Polymorphism Directed Antiemetic treatment in Women With breast cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015-000658-39).
Oliva D; Andersson BÅ; Shamoun L; Lewin N; Nilsson MP; Schildt EB; Fust L; Åsenlund U; Sellerstam G; Elinder E; Sharp L; Lewin F
Anticancer Res; 2023 Jun; 43(6):2671-2681. PubMed ID: 37247895
[TBL] [Abstract] [Full Text] [Related]
19. Are dietary and serum advanced glycation end-products related to inflammation and oxidation biomarkers in breast cancer patients: a follow-up study.
Alkan ŞB; Artaç M; Aksoy F; Belviranlı MM; Gürbilek M; Çizmecioğlu HA; Rakıcıoğlu N
Support Care Cancer; 2023 May; 31(6):334. PubMed ID: 37183232
[TBL] [Abstract] [Full Text] [Related]
20. Serum fatty acid profiles in breast cancer patients following treatment.
Pakiet A; Jędrzejewska A; Duzowska K; Wacławska A; Jabłońska P; Zieliński J; Mika A; Śledziński T; Słomińska E
BMC Cancer; 2023 May; 23(1):433. PubMed ID: 37173619
[TBL] [Abstract] [Full Text] [Related]
[Next]
